Table 1.
Baseline characteristics.
| RYGB (n=11) | SG (n=10) | p | |
|---|---|---|---|
| Age (years) | 48.6 ± 8.9 | 49.5 ± 13.6 | 0.9 |
| Female (n) | 9 | 9 | 1.0 |
| Weight (kg) | 118.6 ± 15.2 | 113.7 ± 17.6 | 0.5 |
| BMI (kg/m2) | 44.1 ± 5.1 | 43.7 ± 5.9 | 0.9 |
| Race/Ethnicity | 0.1 | ||
| White non-hispanic | 9 | 5 | |
| White hispanic | 1 | 1 | |
| African American non-hispanic | - | 4 | |
| African American hispanic | 1 | - | |
| Type 2 Diabetes (n) | 2 | 6 | 0.1 |
| Serum calcium (mg/dl) | 9.5 ± 0.5 | 9.6 ± 0.5 | 0.9 |
| Serum 25-hydoxyvitamin D (ng/ml) | 25.5 ± 5.7 | 31.2 ± 12.7 | 0.2 |
| Serum PTH (pg/ml) | 51.1 ± 16.1 | 62.9 ± 33.9 | 0.3 |
| P1NP (ng/ml) | 50.6 ± 21.9 | 61.1 ± 26.3 | 0.3 |
| CTX (ng/ml) | 0.38 ± 0.1 | 0.49 ± 0.2 | 0.1 |
| DXA | |||
| Spine aBMD (g/cm2) | 1.13 ± 0.11 | 1.19 ± 0.16 | 0.3 |
| Spine T-Score | 0.7 ± 1.0 | 1.0 ± 1.3 | 0.6 |
| Total Hip aBMD (g/cm2) | 1.11 ± 0.15 | 1.08 ± 0.09 | 0.5 |
| Total Hip T-Score | 1.1 ± 0.8 | 0.7 ± 0.9 | 0.3 |
| Femoral Neck aBMD (g/cm2) | 0.94 ± 0.16 | 0.94 ± 0.07 | 1.0 |
| Femoral Neck T-Score | 0.5 ± 1.0 | 0.4 ± 0.7 | 0.6 |
| QCT (mg/cm3) | |||
| Spine vBMD | 169.0 ± 18.3 | 167.0 ± 45.5 | 0.9 |
| Total Hip vBMD | 375.9 ± 51.9 | 355.2 ± 31.7 | 0.3 |
| Femoral Neck vBMD | 375.9 ± 66.8 | 375.6 ± 49.0 | 1.0 |
| Visceral Adipose Tissue (cm2) | 207.8 ± 104.4 | 203.8 ± 111.9 | 0.9 |
| Subcutaneous Adipose Tissue (cm2) | 463.9 ± 123.4 | 502.3 ± 103.5 | 0.5 |
| Marrow Adipose Tissue (lipids/water) | |||
| L1-L2 | 0.65 ± 0.25 | 0.86 ± 0.34 | 0.1 |
| Femoral Metaphysis | 2.3 ± 0.8 | 3.7 ± 2.4 | 0.1 |
| Femoral Diaphysis | 2.9 ± 1.6 | 3.1 ± 1.7 | 0.7 |
RYGB: Roux-en-Y gastric bypass, SG: sleeve gastrectomy; PTH: parathyroid hormone, P1NP: procollagen type 1 N-terminal propeptide; CTX: collagen type 1 cross-linked C-telopeptide; DXA: dual-energy x-ray absorptiometry; QCT: quantitative computed tomography; aBMD: areal bone mineral density; vBMD: volumetric bone mineral density